Shell-and-tube strippers for stripping a urea/carbamate mixture, related systems, methods, and uses. The stripper includes a shell, a plurality of tubes disposed within the shell, and a heating fluid distributor for homogenizing the flow of a heating fluid near a heating fluid inlet. The heating fluid distributor includes an edge wall and a laterally disposed heating fluid distribution plate. Related systems, methods, and uses are also provided.

Shell-and-tube strippers for stripping a urea/carbamate mixture, related systems, methods, and uses. The stripper includes a shell, a plurality of tubes disposed within the shell, and a heating fluid distributor for homogenizing the flow of a heating fluid near a heating fluid inlet. The heating fluid distributor includes an edge wall and a laterally disposed heating fluid distribution plate. Related systems, methods, and uses are also provided.

Described herein are methods for quantitatively determining the amount of the amphetamine-related compound identified herein as amphetamine carbamate (amphetammonium-amphetacarbamate) present in a drug-containing polymer matrix comprising amphetamine, and for assessing a drug-containing polymer matrix comprising amphetamine. The methods may comprise converting any amphetacarbamate present into reaction products comprising carbonate, quantifying the amount of carbonate, and quantifying the amphetacarbamate originally present from the quantified amount of carbonate.

Described herein are methods for quantitatively determining the amount of the amphetamine-related compound identified herein as amphetamine carbamate (amphetammonium-amphetacarbamate) present in a drug-containing polymer matrix comprising amphetamine, and for assessing a drug-containing polymer matrix comprising amphetamine. The methods may comprise converting any amphetacarbamate present into reaction products comprising carbonate, quantifying the amount of carbonate, and quantifying the amphetacarbamate originally present from the quantified amount of carbonate.

The present invention relates to a newly identified solvate form of (i?)-2-amino-3-phenylpropyl carbamate (APC) hydrochloride, a method of preparing APC hydrochloride, and methods of using the same to treat disorders. The invention further relates to methods of producing APC hydrochloride with increased purity.

The present invention relates to a newly identified solvate form of (i?)-2-amino-3-phenylpropyl carbamate (APC) hydrochloride, a method of preparing APC hydrochloride, and methods of using the same to treat disorders. The invention further relates to methods of producing APC hydrochloride with increased purity.

The present invention provides a method for producing an active ingredient for a rivastigmine free base transdermal patch having preparing a rivastigmine free base; and adding an acidic substance to the rivastigmine free base and subjecting the acidic substance and the rivastigmine free base to a mixed reaction to form a mixture having a pH value from 6.0 to 8.5 as the active ingredient; and a rivastigmine free base transdermal patch having a drug layer comprising the active ingredient. The rivastigmine free base transdermal patch has a stable transdermal transmission time equal to or longer than 48 hours and equal to or less than 168 hours. The active ingredient produced by the method and the transdermal patch having the active ingredient allow effective and smooth release of rivastigmine free base and prolongs the release time to meet the clinical application needs.

The present invention provides a method for producing an active ingredient for a rivastigmine free base transdermal patch having preparing a rivastigmine free base; and adding an acidic substance to the rivastigmine free base and subjecting the acidic substance and the rivastigmine free base to a mixed reaction to form a mixture having a pH value from 6.0 to 8.5 as the active ingredient; and a rivastigmine free base transdermal patch having a drug layer comprising the active ingredient. The rivastigmine free base transdermal patch has a stable transdermal transmission time equal to or longer than 48 hours and equal to or less than 168 hours. The active ingredient produced by the method and the transdermal patch having the active ingredient allow effective and smooth release of rivastigmine free base and prolongs the release time to meet the clinical application needs.

Processes for preparing acetylated amphetamine derivatives and, in particular, processes for preparing L-lysine-D-amphetamine dimesylate from D-amphetamine salts.

Processes for preparing acetylated amphetamine derivatives and, in particular, processes for preparing L-lysine-D-amphetamine dimesylate from D-amphetamine salts.